ArticleGenes & diseases2026

Optimal combination of immune cells for predicting outcomes in ESCC patients following neoadjuvant immunochemotherapy: Results from a prospective phase II trial.

Peipei Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.